WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

Spinoff

MiniMed starts trading on its own as Medtronic swaps out its last 252.8 million shares

MedDevice Startups Staff · 6 days ago · 2 min read · Via MassDevice

Medtronic closed out its diabetes business on October 14, when it reported the final results of the exchange offer that moved its remaining MiniMed stake to its own shareholders. MiniMed began trading independently on Nasdaq the next day under the ticker MMED.

The offer expired at the end of October 9 and came in oversubscribed, so Medtronic filled it on a pro rata basis at a proration factor of 18.289133 percent. It handed over 252,813,348 MiniMed shares in exchange for 55,032,401 of its own ordinary shares, at a final ratio of 4.5939. Medtronic retains none of MiniMed.

CEO Que Dallara said the company now has the freedom to make the decisions it believes are right for its business. A split-off gets the parent all the way out in one step, rather than leaving a stub stake to sell down over the following year.

Questions & Answers

How did Medtronic separate MiniMed?

Medtronic used a split-off exchange offer, letting its own shareholders trade Medtronic ordinary shares for MiniMed stock. On October 14, 2026 it reported final results and said it would retain none of MiniMed.

What ticker does MiniMed trade under?

MiniMed trades on Nasdaq under the ticker MMED. Its first day as a fully independent company was October 15, 2026.

What was the exchange ratio in the Medtronic MiniMed split-off?

The final ratio was 4.5939 MiniMed shares per Medtronic ordinary share. Medtronic exchanged 252,813,348 MiniMed shares for 55,032,401 of its own shares, prorating an oversubscribed offer at 18.289133 percent.

← Back to M&A